| A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease (NCT05398029) | Verve Therapeutics, Inc. | 2022-07-05 |
| A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). (NCT05325203) | Shanghai Junshi Bioscience Co., Ltd. | 2021-12-31 |
| Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (NCT04797104) | LIB Therapeutics LLC | 2021-04-22 |
| Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C (NCT04666298) | Novartis Pharmaceuticals | 2021-01-29 |
| Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia (NCT04759534) | Shenzhen People's Hospital | 2020-09-10 |
| Safety and Efficacy of IBI306 in HeFH Patients (NCT04179669) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-12-20 |
| A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) (NCT04173793) | Akeso | 2019-11-18 |
| Long Term Safety Study of PRALUENT (NCT03694197) | Regeneron Pharmaceuticals | 2018-09-28 |
| Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) (NCT03397121) | The Medicines Company | 2017-11-28 |
| Lp(a) and Aortic Valve Calcification (NCT02976818) | Laval University | 2017-04-30 |
| Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) (NCT03038022) | Madrigal Pharmaceuticals, Inc. | 2017-02-23 |
| Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders (NCT02392559) | Amgen | 2016-03-24 |
| Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (NCT02326220) | Regeneron Pharmaceuticals | 2015-03-31 |
| A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (NCT01968980) | Pfizer | 2013-10-23 |
| Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) (NCT01709500) | Regeneron Pharmaceuticals | 2012-12-01 |
| A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) (NCT01583647) | Merck Sharp & Dohme LLC | 2012-06-01 |
| Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) (NCT01576484) | Regeneron Pharmaceuticals | 2012-02-28 |
| Exploratory Study of Plaque Regression (NCT01515241) | Cerenis Therapeutics, SA | 2012-01-01 |
| Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia (NCT03563547) | Austrian Academic Institute for Clinical Nutrition | 2009-09-03 |
| Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease (NCT00706849) | Kastle Therapeutics, LLC | 2008-07-01 |
| Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE. (NCT00151788) | Daiichi Sankyo | 2004-02-01 |
| Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia (NCT00171236) | Novartis | 2001-10-01 |